FAST Australia is committed to advancing Australian research while maintaining a strong collaborative relationship with FAST United States and global patient organisations.
We focus our efforts on determining areas of unmet Angelman syndrome research in line with the global vision for a cure and identify opportunities to fund research to address those gaps. Read more about how/where we have invested funds in research below.
Enabling
Tools & resources that will allow research into our ultimate goal to progress.
- Global Angelman Syndrome Registry
- Registry Curator/ Research Assistant (Mater Research Institute)
- TranSMART analytical platform (Clarivate Analytics)
- Generation of an Angelman syndrome model cell line (University of Sydney)
- Generation of mouse lines expressing human UBE3A antisense (co-funded with FAST United States)
- Development and characterisation of a pig model of AS (co-funded with FAST United States)
- Quantifying EEG Abnormalities and identifying biomarkers in Angelman syndrome (Co-funded with the Angelman Syndrome Alliance)
Learning
Basic science that will help us understand more about the syndrome to propel research.
- RNA binding motifs as therapeutic targets for Angelman syndrome (University of Sydney)
- Expression profiling for mechanisms of minocycline action (Queensland Bioinformatics)
- Health Economics in Angelman syndrome
- Incidence of Food Sensitivity and Gut Dysbiosis in Angelman syndrome
(Co-funded with FAST United States and FAST United Kingdom)
Treatments
Discovering therapeutics that alleviate one or more symptoms of Angelman syndrome
- Potential therapeutic approach for synaptic deficit in Angelman syndrome
(Co-funded with the Angelman Syndrome Alliance)
